SUMMARY A commonly used estimate of a screening test's sensitivity, based on the prevalence at screening and the incidence of interval cancers, is shown to be logically unsound and quantitatively poor. An alternative simple estimate is proposed, based only on incidence rates.
The purpose of this note is to draw attention to an estimate of the sensitivity of a screening test for the early detection of disease which is in common use and appears to be incorrect. The usual definition of the sensitivity of a screening test is in terms of the following schematic two by two table:
True Disease State +_ Screening test
The sensitivity is defined as the proportion of individuals with disease whom the screening test labels positive, that is, sensitivity = S = a/(a+c)
The specificity is given by d/(b+d). Estimation of specificity is a separate problem and for qase of presentation it will be assumed that the specificity is 100%. Unless all individuals are subjected to a definitive diagnostic test, which in most situations would not be acceptable, the sensitivity is not directly estimable. In particular, the quantity c, the number of individuals screened negative who in fact have the disease, will not be known.
An estimate of sensitivity which is being increasingly used is based on the assumption that those incorrectly screened negative will surface with clinical manifestation of the disease in a short interval after the screen. An interval often used is 1 year.1 The quantity c is then estimated by the number of cases of disease occurring in the year after screening, which will be denoted by c*, and the estimate of sensitivity, 9 say, given by S = Estimate of sensitivity = a+c (1) This estimate, which on first view might appear a reasonable approximation, can be seriously wrong. The 2 x 2 table given above, although attractively simple, ignores the time aspect of early detection. The lesions potentially identifiable by the screening test are those in the preclinical detectable phase, or PCDP. At a particular point in time the number of individuals in the PCDP is given by the incidence of the disease (I) multiplied by the average duration (IL) of the PCDP (assuming 100% specificity). The number of lesions detected will be the number that are prevalent multiplied by the sensitivity. That is, assuming b=0, Lesions detected at (first) screening = S.I.,=a In the year after screening, incident cases of disease will consist ofthose cases in the PCDP at screening but missed, and those cases whose PCDP began after the screening test, with duration less than a year. The estimate given by expression ( 1) has two sources of error. The denominator omits all cases which were missed at the screening test but do not surface until more than a year has elapsed, and includes cases which surface in the first year but were not in the PCDP at the time of the test. An assessment of the quantitative effect of these two sources of error can be made as follows.
The number of cases surfacing in the year after screening, whose PCDP began after the screening test, can be evaluated in terms ofthe distribution of the PCDP.2 If F(t) denotes the cumulative distribution function of the PCDP, thus giving the proportion of lesions with a PCDP less than or equal to t, the incidence (ie, integrated incidence rate) of new cases arising in the first year after screening is given by
Of those surfacing at time t after the screening test who were missed at the test, the PCDP must have been greater than or equal to t. The incidence rate of these cases is therefore I( 1-S) [ l-F(t)], and the overall incidence in the first year is given by 364
The sum of these two components is thus One can see from expression (2) that the sensitivity and the left-hand tail of the distribution of the PCDP both contribute to the incidence of early interval cancers. Methods have been proposed for obtaining separate estimates of S and F(t),3 but the computation is laborious.
One approach to forming a simple estimate of S which performs better than S might be to correct S according to expression (3) to obtain a refined estimate SI given by
Unfortunately, this estimate requires knowledge both of, I and of f F(t)dt, and will be seriously in error if a wrong 0 assumption is made for j. f(t)dt is simply the proportion of cases with a-PCDP of 0 duration less than time T. In the absence of any knowledge ofF(t), one can go no further than assertingl-IT/I -92 < 1-When screening for breast cancer, however, a reasonable approximation would be that F is exponential with mean about two years.5 For cervical cancer screening, F could be taken as exponential with mean 15 years.4 Ifone takes T to be fairly small compared to the estimate of the mean, then the denominator of 92 will be close to one, and relatively insensitive to errors in the estimate of the mean. Assuming the distribution of the PCDP to be exponential with mean two years, and taking the incidence in the first six months after screening, then Table 2a shows the result of using this estimate for various values of S if the correct value of the mean differs from 2. These two proposed estimates of sensitivity should not be regarded as being in any sense optimum. They are proposed solely as simple estimates with a more secure logical foundation than the commonly used estimate 9. 
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